SecBot SecBot
8-K ·Filed Apr 17, 2026

LYRA

Lyra Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago SEC0001193125-26-160421
8-K material event: Items 1.02
Actionable Insight ▼ Bearish

The termination suggests Lyra is consolidating or downsizing operations, likely to conserve cash. The $2.1 million termination fee represents a material near-term cash outflow for a small-cap biotech, potentially pressuring liquidity. Traders should monitor upcoming financials for signs of cost-cutting or reduced operational footprint.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
LYRA ▼ -47.53% at T+60d
SHORT call ✓ call won +47.53% · α vs SPY +53.68% · entry $0.8046 → $0.4221
Entry = T+0 close
Apr 17, 2026
via day close
T+1d
-7.28%
call +7.28% · α +7.09%
$0.7460
settled 6mo ago
T+5d
-11.68%
call +11.68% · α +12.24%
$0.7106
settled 6mo ago
T+20d
-6.79%
call +6.79% · α +12.16%
$0.7500
settled 6mo ago
T+60d
-47.53%
call +47.53% · α +53.68%
$0.4221
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Lyra Therapeutics terminated its sublease for 23,704 square feet in Waltham, Massachusetts, effective March 31, 2026, after agreeing to pay a $2.1 million termination fee. The company ceased rent payments as of January 31, 2026, and will recover a $600,501 security deposit upon surrendering the premises by May 31, 2026.

Key Facts

  • Terminated sublease at 880 Winter Street, Waltham, MA, effective March 31, 2026
  • Company agreed to pay $2,100,000 termination fee
  • Rent obligations ended January 31, 2026
  • Security deposit of $600,501.32 to be returned upon surrender of premises by May 31, 2026
  • Sublease originally dated December 21, 2023

Financial Impact

Immediate cash outflow of $2.1 million with recovery of $600,501 deposit, resulting in net cash cost of $1.5 million

cash flowoperating expensesliquidity

Risk Factors

  • Significant near-term cash outflow of $2.1 million could strain liquidity
  • Potential operational disruption from relocating or consolidating facilities
  • Possible signal of financial distress or strategic retrenchment

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-160421
Document: 0001193125-26-160421-index-headers.html0001193125-26-160421
Document: 0001193125-26-160421-index.html0001193125-26-160421
Document: 0001193125-26-160421.txt0001193125-26-160421
4 reports for LYRA
Performance horizon
67% Hit rate @ T+60 2 of 3 directional calls Went positive at some point 2 of 3 best @ T+60▲ +47.53%Apr 17, 2026
Filters
Rows
Reports for LYRA — sortable, filterable
TypeNow
Apr 30, 2026
25w ago
15-12G
BEARISH ★ 7/10
$0.7050 $0.5200▲ +26.24%▲ +29.35%$0.1900 (+73.05%)
Apr 17, 2026
27w ago
8-K
BEARISH ★ 6/10
$0.8046 $0.4221▲ +47.53%▲ +53.68%$0.1900 (+76.39%)
Apr 17, 2026
27w ago
Press Release
BEARISH ★ 8/10
$0.8046 $0.4221▲ +47.53%▲ +53.68%$0.1900 (+76.39%)
Apr 10, 2026
28w ago
8-K
BEARISH ★ 7/10
$0.6500 $0.7093▼ −9.13%▲ +1.20%$0.1900 (+70.77%)
Showing 4 of 4

US Market Status

Market Open — Closes in 1h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026